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RPTP is a cell adhesion molecule-like receptor protein tyrosine phosphatase involved in nervous system
development. Its avian orthologue, known as cPTP or CRYP, promotes intraretinal axon growth and
controls the morphology of growth cones. The molecular mechanisms underlying the functions of cPTP are
still to be determined, since neither its physiological ligand(s) nor its substrates have been described. Never-
theless, a major class of ligand(s) is present in the retinal basal lamina and glial endfeet, the potent native
growth substrate for retinal axons. We demonstrate here that cPTP is a heparin-binding protein and that its
basal lamina ligands include the heparan sulfate proteoglycans (HSPGs) agrin and collagen XVIII. These
molecules interact with high affinity with cPTP in vitro, and this binding is totally dependent upon their
heparan sulfate chains. Using molecular modelling and site-directed mutagenesis, a binding site for heparin
and heparan sulfate was identified in the first immunoglobulin-like domain of cPTP. HSPGs are therefore a
novel class of heterotypic ligand for cPTP, suggesting that cPTP signaling in axons and growth cones is
directly responsive to matrix-associated cues.
The complex pattern of neural connectivity established dur-
ing nervous system development relies on the ability of the
axon’s motile tip, the growth cone, to receive, transduce, and
integrate multiple environmental signals. Protein phosphory-
lation on tyrosine residues plays a key role in these processes
(21, 29). Two major families of enzymes, the protein tyrosine
kinases and the protein tyrosine phosphatases (PTPs), control
cellular phosphotyrosine levels. These enzymes are found in
both cytoplasmic and transmembrane (receptor-like) forms,
and the biochemical interactions between them lead to a di-
versity of cellular behaviors (25, 76).
Receptor protein tyrosine phosphatases (RPTPs) have re-
cently joined the list of molecules involved in neural develop-
ment and in particular in axon growth and guidance (reviewed
in references 6, 68, 72, and 79). Type 2 RPTPs, containing cell
adhesion molecule (CAM)-like extracellular regions, may be
particularly well equipped to trigger signals involving cell-cell
or cell-extracellular matrix contacts (68). Recent experiments
with Drosophila have demonstrated the involvement of the
RPTPs DLAR and DPTP69D in motor (19, 20, 50), retinal (27,
57), and midline (73) axon guidance. In leech, a LAR gene-
related RPTP (HmLAR2) is implicated in Comb cell behavior,
specifically in process outgrowth and mutual avoidance by sib-
ling growth cones (2, 28). Several vertebrate RPTPs have been
shown to promote neurite outgrowth in cell culture, including
cPTP (51), RPTP (23), RPTP (10), and RPTP (82).
Moreover, it has recently been shown that RPTP also has a
potential guidance function, at least in vitro (74).
In mice, gene deficiencies in type 2 RPTPs lead to various
abnormalities. LAR deficiency leads to a reduction in size of
basal forebrain cholinergic neurons, diminished hippocampal
innervation, and defects in other tissues, such as the mammary
gland (63, 78, 86). RPTP deficiency leads to impaired learning
and enhanced hippocampal long-term potentiation (77). The
most extreme defects are seen in RPTP-deficient mice, which
show poor fecundity, hypomyelination of peripheral nerves,
ataxias, and abnormalities in development of the hypothala-
mus and pituitary (24, 80). Although the developmental mech-
anism of these defects is not known, it is of interest that the
avian orthologue of RPTP, cPTP (69, 85), regulates axon
outgrowth of embryonic neurons (51).
Despite this accumulation of functional data, much less is
known about the extracellular cues that trigger signal trans-
duction though RPTPs. Several RPTPs interact homophilically
in trans, including RPTP (8), RPTP (62), and RPTP (82),
but the effects of such homophilic interactions on enzyme
function are as yet unclear. The laminin-nidogen complex has
been shown to be a heterotypic ligand for a nonneural isoform
of LAR (59), while type 5 RPTP can bind to several mole-
cules, including contactin and tenascin and the cytokines mid-
kine and pleiotrophin (60). Significantly, pleiotrophin has also
recently been shown to suppress the catalytic activity of RPTP
(53).
cPTP, originally described as CRYP (69), is a type 2
RPTP expressed as two major isoforms: cPTP1 (CRYP1)
has three immunoglobulin-like (Ig) domains and four fibronec-
tin type III (FNIII) domains in its extracellular region, while
cPTP2 (CRYP2) has four extra FNIII domains. Both iso-
forms are strongly expressed in the chicken embryo nervous
system, in particular within retinal and tectal axons and on
their growth cones (70, 71). Moreover cPTP1 promotes in-
traretinal axon growth in vitro and controls growth cone mor-
phology via the maintenance of lamellipodia (51). One or more
ligands for cPTP are localized in the retinal and tectal basal
lamina (BL) and on the glial endfeet of these tissues (33, 51),
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but the identity of these ligands has remained elusive. To
understand how cPTP may function at the molecular and
cellular levels, we sought to identify the molecular nature of
these ligands. Here we show that cPTP is a heparin binding
protein and that extracellular matrix heparan sulfate proteo-
glycans (HSPGs), in particular agrin and collagen XVIII, are
binding partners for cPTP in vitro. Receptor affinity probe
assays on tissue sections reveal that the binding of cPTP
ectodomains to HSPGs is absolutely dependent on the pres-
ence of heparan sulfate (HS) side chains. Site-directed mu-
tagenesis in a putative heparin and HS (heparin/HS) binding
site in cPTP completely abolished this interaction. These
data, together with the overlapping expression patterns of
cPTP, agrin, and collagen XVIII in the developing chick
retina, suggest that the reported interactions are physiologi-
cally relevant and that HSPGs could be a major ligand class for
cPTP.
MATERIALS AND METHODS
Expression constructs, fusion protein production, and site-directed mutagen-
esis. The pBG plasmid was constructed by subcloning the HindIII-XbaI fragment
coding for human placental alkaline phosphatase (AP) from APTag2 (13) into
pcDNA3.1 (Invitrogen). A HindIII fragment coding for the extracellular region
of cPTP1 (amino acids 1 to 721; GenBank accession number L32780) was
subcloned into pBG, in frame with AP, resulting in pBG1-AP. pBG1-AP was
transfected into 293T cells (grown in Dulbecco’s modified Eagle medium, 10%
fetal calf serum, 1% penicillin-streptomycin mixture; sigma) using Superfect
(Qiagen). Conditioned medium containing the secreted cPTP1-AP fusion pro-
tein was collected after 6 to 7 days, sterile filtered, buffered to pH 7.4 with 20 mM
HEPES, and stored at 4°C. The fusion protein was quantified by measuring the
AP activity as described previously (17).
The p1VST expression vector was constructed by subcloning the HindIII
fragment coding for the cPTP1 extracellular region into the pCS3N-VST shut-
tle vector (A. R. Aricescu and A. W. Stoker, unpublished data), which contains
a HindIII site, a linker coding for the vesicular stomatitis virus (VSV) peptide
tag, a spacer sequence, and an AclI site, all flanked by two NotI sites. p1VST
was used to express the secreted cPTP1-VSV fusion protein in 293T cells as
described above, or for higher expression levels, the cPTP1-VSV coding frag-
ment was transferred into the RCAS(A) avian retrovirus (46) as follows: p1VST
was linearized with AclI and ligated into the ClaI opened RCAS(A); the shuttle
vector backbone was then removed via NotI digestion and self-ligation, resulting
in the RCAS-1VST retrovirus. This construct was transfected into line 0
chicken embryo fibroblasts (grown in Dulbecco’s modified Eagle medium plus
10% fetal calf serum plus 2% chick serum) using Superfect. After six passages
the conditioned medium containing cPTP1-VSV was collected, sterile filtered,
and buffered to pH 7.4 with 20 mM HEPES.
The pFN3-AP expression plasmid, containing a cPTP1 extracellular con-
struct lacking the membrane-proximal FNIII-like domain, fused to the amino
terminus of AP, was a gift from John Chilton. This plasmid was used as a
template for site-directed mutagenesis according to Stratagene’s QuickChange
mutagenesis kit protocol. Primer sequences can be obtained from A. R. Aricescu.
All mutant constructs were verified by DNA sequencing and transfected into
293T cells, and conditioned media were collected as described above.
Solid-phase binding assays. Heparin-albumin (Sigma), agrin (purified as de-
scribed in reference 36), and collagen XVIII (purified as described in reference
38) were immobilized on 96-well microtiter plates at a concentration of 2 g/ml
(heparin-albumin) or 5 g/ml (agrin and collagen XVIII) for 2 h at room
temperature. Remaining binding sites were saturated by overnight incubation at
4°C in phosphate-buffered saline (PBS) buffer (137 mM NaCl, 2.7 mM KCl, 8.1
mM Na2HPO4, 1.5 mM KH2PO4 [pH 7.4]) containing 3% bovine serum albumin
(BSA). Wells were incubated for 3 h at room temperature with conditioned
media from 293T cultures, containing AP fusion proteins. After four washes in
PBS and one wash in SEAP buffer (0.5 mM MgCl2, 1 M diethanolamine [pH
9.8]), the bound AP activity was determined by adding 200 l SEAP buffer
containing 10 mM p-nitrophenyl phosphate. Progress curves were recorded for
1 h at room temperature, at 405 nm, using a Dynex MRX microplate reader, and
the initial rates were determined using the SigmaPlot 4.01 software (SPSS, Inc.).
Each data point represents the average of triplicate wells 	 the standard devi-
ation. Nonspecific binding was determined from cPTP1-AP bound to BSA
(immobilized at a concentration of 3 mg/ml) and was subtracted from each data
point.
The data were plotted for Scatchard analysis in order to get initial estimates of
the binding parameters. cPTP1-AP was found to bind HSPGs with very high
affinities, and at low concentrations, more than 10% of the initial AP activity was
bound. Therefore, in order to obtain more accurate Kd values, we fitted the
saturation curve by nonlinear regression to the following equation, which takes
into account significant ligand depletion, with negligible nonspecific binding (75):
b*tot
2 
 b*tot[(Kd  L*tot)  rtot]   L*tot rtot  0, where b*tot is the total
amount of bound ligand (cPTP1-AP) expressed in optical density units (OD)
per minute,  is the specific AP activity expressed in OD per minute per molar
concentration units, Kd is the equilibrium dissociation constant, L*tot is the total
ligand (cPTP1-AP) concentration, and rtot is the maximal specific binding
expressed in OD per minute. The specific activity used for cPTP1-AP fusion
protein was 1.12 OD/min/nM.
In vivo viral injection. White Leghorn eggs were obtained from Needle Farm
(Herts) and incubated at 38°C to the desired stage. The RCAS-1VST vector
was used to generate stocks of viral inoculi as described previously (54). Virus
(0.1 l) was injected into the optic vesicle of stage 11 embryos (33 h) (40) using
a PM1000 microinjector (MicroData Instrument Inc.). E6 embryos were pro-
cessed for immunohistochemistry or in situ hybridization.
Immunohistochemistry and in situ hybridization. E6 or E10 chicken embryo
heads were fixed in 4% paraformaldehyde in PBS, cryoprotected in 30% sucrose
in PBS, and frozen in OCT compound (TissueTek). Cryosections (10 to 12 m)
were mounted on 3-aminopropyltriethoxysilane-coated glass slides. For immu-
nohistochemistry, sections were blocked with 1% BSA–0.25% Triton X-100 in
PBS for 15 min at room temperature. Primary antibodies used were IG2 (anti-
cPTP rabbit polyclonal) (70) diluted at 1:500; P5D4 (anti-VSV glycoprotein
monoclonal; Sigma) at 1:500; 6D2 (anti-agrin monoclonal) (35) at 1:20, and 6C4
(anti-collagen XVIII monoclonal) (38) at 1:20, all in 3% BSA–0.25% Triton
X-100 in PBS. After 1 h of incubation at room temperature, the sections were
washed three times in 0.1% BSA–0.05% Triton X-100 in PBS and secondary
antibodies were added for 1 h at room temperature: goat anti-rabbit peroxidase-
conjugated (Promega), diluted at 1:100; rabbit anti-mouse peroxidase-conju-
gated (Promega), at 1:100; and goat anti-mouse fluorescein isothiocyanate-con-
jugated (Jackson Labs), at 1:200. After three final washes the peroxidase
reactions were performed using the DAB substrate kit (Vector Laboratories);
the fluorescein isothiocyanate-labeled sections were mounted in Fluorosave
(Calbiochem), and all sections were analyzed using an Axiophot fluorescence
microscope (Zeiss).
For in situ hybridization, the PRD4A viral probe (58) was used, as described
previously (52).
Receptor affinity probe (RAP) in situ. The in situ localization of cPTP ligands
on tissue sections and flat-mounted retinal basal laminae was performed using
the cPTP1-AP conditioned medium, as previously described (33, 51). In mod-
ified RAP assays, the cPTP1-AP probe was preincubated with 100 g of heparin
(Sigma), bovine kidney HS (Sigma), or chondroitin sulfate (Calbiochem)/ml for
1 h at room temperature before addition to the tissue samples. Alternatively, the
tissue samples were pretreated for 2 h at 37°C with 0.5 U of heparinase III
(Sigma) in 50 l of PBS, pH 7.4, containing 0.1% BSA or with 0.1 U of
chondroitinase ABC (Sigma) in 50 l of Tris-acetate buffer, pH 8. The protease
inhibitor 4-(2-aminoethyl)-benzenesulfonyl fluoride was added to both reactions
at a final concentration of 2 mM.
Immunoblotting and blot-overlay assays. An HSPG-enriched fraction (HfV)
from E9 chicken embryo vitreous bodies homogenized in Ca2-free and Mg2-
free Hanks’ balanced salt solution, pH 7.3 (CMF), was partially purified by
ion-exchange chromatography as follows. The vitreous homogenate was supple-
mented with 1:100 protease inhibitors cocktail with no metal chelators (Sigma)
and centrifuged at 12,000  g for 30 min at 4°C to remove debris. The super-
natant was applied on a Q-Sepharose Fast Flow column (Amersham Pharmacia
Biotech) and washed with 0.5 M NaCl in CMF, and the HfV fraction was eluted
with 1.5 M NaCl in CMF. Eluted fractions were concentrated on a Centricon
YM-30 (Amicon), and the buffer was changed to CMF. Aliquots of the HfV, 100
ng of immunopurified agrin, and collagen XVIII (as described in references 36
and 38) were preincubated for 2 h at 37°C with either 0.5 U of heparinase III, 0.1
U of chondroitinase ABC, or 0.1 U of collagenase (Sigma type VII) in PBS, pH
7.4, containing 2 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride.
For immunoblotting, the reactions were mixed with equal volumes of Laemmli
sample loading buffer (62 mM Tris [pH 6.8], 2% sodium dodecyl sulfate (SDS),
10% glycerol, 5% -mercaptoethanol, 0.001% bromophenol blue), boiled, and
separated by SDS–6% polyacrylamide gel electrophoresis. Proteins were trans-
ferred onto Hybond-C Extra nitrocellulose membranes (Amersham Pharmacia
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Biotech), blocked overnight at 4°C in 5% nonfat milk in PBS, and probed for 1 h
at room temperature with antiagrin (6D2; 1:20) or anticollagen XVIII (6C4;
1:20) monoclonal antibodies. The secondary antibody used was rabbit anti-
mouse horseradish peroxidase (Dako) diluted at 1:2,000. Chemiluminescence
detection was performed using the ECL Western blotting kit (Amersham Phar-
macia Biotech).
For blot overlay assays, the samples were processed as described above except
that following overnight blocking, the membranes were incubated for 3 h at room
temperature with cPTP1-VSV conditioned medium supplemented with 0.5%
Igepal CA-630 (Sigma). The membranes were then washed three times with PBS
containing 0.5% Igepal CA-630, and bound cPTP1-VSV was detected using the
anti-VSV monoclonal antibody (P5D4; 1:1,000) as described above.
Homology modelling of cPTP domains. Individual domains of the extracel-
lular region of cPTP were defined using the Pfam server (http://www.sanger
.ac.uk/Pfam [5]). The corresponding sequences were submitted to the SWISS-
MODEL v3.5 protein modelling server (http://www.expasy.ch/swissmod/SWISS
-MODEL.html [31]) for analysis. Suitable modelling templates were identified in
the ExNRL-3D database using SWISS-MODEL Blast. The sequence alignments
obtained were analyzed, and the most appropriate ExPDB entries were selected
as templates. All the models generated were quality checked by the WHAT IF
verification routines (WHAT-CHECK [45]) and the Biotech protein validation
suite (http://biotech.embl-heidelberg.de:8400/). Energy minimization was done
with the GROMOS implementation of Swiss-PdbViewer v3.6b2 (30) (http://
www.expasy.ch/spdbv/).
RESULTS
cPTP binds to the retinal BL in vivo and in vitro. Our
previous results established that the BL and glial endfeet of the
chicken embryo retina, optic stalk, and chiasm contain a prom-
inent ligand for the cPTP1 ectodomain (33). This was de-
tected in vitro using the cPTP1-AP fusion protein in a RAP
in situ technique (26).To test whether a related binding pattern
occurs in vivo, we constructed the RCAS-1VST retrovirus
that encodes a secretable cPTP1 ectodomain fused with the
VSV peptide tag (cPTP1-VSV). cPTP1-VSV was readily
detected as it accumulated in conditioned medium from in-
fected cells in culture (Fig. 1A). RCAS-1VST virus was in-
jected into the optic vesicle of chick embryos at stage 11 (33
h), and by embryonic day 6 (E6) the retrovirus had infected the
whole retina (Fig. 1B). The cPTP1-VSV protein, secreted by
infected retinal cells in situ, accumulated specifically in the
ligand-rich BL region (Fig. 1D), providing good evidence in
vivo that at least one physiological ligand for cPTP is located
in this region.
cPTP is a heparin-binding protein. We screened for re-
agents that could modulate RAP in situ binding of the cPTP
ectodomain to the retinal BL. Increasing concentrations of
sodium chloride abolished this interaction, whereas the non-
ionic detergent Igepal CA-630 had no effect even at high con-
centrations. We hypothesized therefore that the cPTP-ligand
interaction was predominantly ionic rather than hydrophobic
and that it may involve charged glycosaminoglycan chains.
Using a secreted cPTP1 ectodomain fused with AP at its C
terminus (cPTP1-AP) (33), we found that in solid-phase
binding assays cPTP1-AP bound to heparin-albumin at sub-
nanomolar concentrations (Fig. 2A). Using a nonlinear regres-
sion analysis, a Kd value of 0.32 	 0.05 nM was calculated,
demonstrating that cPTP binds heparin with very high affin-
ity. Control constructs containing AP alone or AP fused with
the ectodomain of RPTP did not bind to heparin-albumin in
similar assays (data not shown). In addition, the nonspecific
binding of cPTP1-AP on wells coated just with albumin was
negligible (data not shown). Therefore, we propose that the
cPTP1-AP construct binds heparin via the extracellular re-
gion of cPTP.
cPTP binds to retinal HSPGs. We next investigated
whether ligand interactions detected in RAP assays (33) are
mediated by HS chains and whether heparin and soluble HS
can compete in binding. Preincubation of cPTP1-AP condi-
tioned medium with heparin completely blocked the BL signal
(Fig. 3B). HS also interfered with binding but did not com-
pletely block it (Fig. 3C); this may be due to the type of HS we
used (bovine kidney), since it is known that significant varia-
tions in the HS structure (the degree of sulfation, for example)
exist between different tissues. No effect was observed when
cPTP1-AP was preincubated with the same amount of chon-
droitin sulfate (Fig. 3D), itself a highly charged polyanionic
molecule.
To establish whether heparin and HS modulate the binding
because they bound cPTP1-AP directly, or because they sim-
ply masked the binding site(s) on the BL ligand, the sections
were pretreated with heparinase III or chondroitinase ABC.
Heparinase III completely removed the BL signal (Fig. 3E),
while chondroitinase ABC had no effect (Fig. 3F). Therefore,
we conclude that the cPTP1-AP binding observed on the
FIG. 1. Binding of cPTP to the E6 chick retinal basal lamina in
vivo. (A) Time course of cPTP1-VSV production by chicken embryo
fibroblasts infected with RCAS-1VST retrovirus. Samples of culture
medium conditioned for 1 (lane 2), 2 (lane 3) or 3 (lane 4) days after
transfection were analyzed by immunoblotting using antibody specific
for the VSV epitope. Lane 1 contains conditioned medium from un-
transfected cells. (B and D) RCAS-1VSV retrovirus-infected retinas
at E6, probed with a digoxigenin-labeled viral probe by in situ hybrid-
ization (B) or with VSV antibody (D). Noninfected tissues were
probed by in situ hybridization (C) or with VSV antibody (E). Arrow-
heads indicate the retinal BL. pe, pigmented epithelium. Scale bar, 0.1
mm.
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retinal BL is mediated by HS chains and (since free heparin is
not present in the retina) that the ligand(s) is an HSPG(s).
cPTP binds to the extracellular matrix HSPGs agrin and
collagen XVIII. The major HSPGs present in the retinal BL
are agrin and collagen XVIII (39). Perlecan can also be de-
tected at very low levels. Agrin and collagen XVIII immuno-
purified from the vitreous body (36, 38) were tested as candi-
date ligands for cPTP in solid-phase binding assays.
cPTP1-AP bound at picomolar concentrations to both agrin
and collagen XVIII (Fig. 2B and C). The equilibrium dissoci-
ation constants measured were 0.18 	 0.01 nM for agrin and
0.21 	 0.02 nM for collagen XVIII, demonstrating that cPTP
binds these HSPGs with very high affinity. This experiment
shows that native agrin and collagen XVIII behave as potential
ligands for cPTP, at least in vitro.
These interactions were investigated in a further assay to
determine whether cPTP-proteoglycan interactions do occur
mainly via the HS chain, as predicted above. An HSPG-en-
riched (HfV) fraction from E9 chicken embryo vitreous bodies
was prepared by ion-exchange chromatography and, together
with pure agrin and collagen XVIII, was tested on a blot
overlay assay. The HfV fraction contained both agrin and
collagen XVIII (Fig. 4A). Agrin, a large proteoglycan with an
apparent molecular mass of 500 kDa, appeared in the HfV
fraction and was not digested by treatment with collagenase
FIG. 2. Saturation curves and Scatchard plots for the binding of
cPTP to heparin, agrin, and collagen XVIII. Microtiter plates were
coated with heparin-albumin (A), agrin (B), or collagen XVIII (C) and
incubated with a range of cPTP1-AP concentrations. Saturation
curves were fitted by nonlinear regression analysis as described in
Materials and Methods. Each value represents the mean 	 standard
deviation of three measurements.
FIG. 3. Binding of cPTP to the E6 chick retinal BL is mediated by
HS chains. Results of receptor affinity probe assays using the extracel-
lular region of cPTP1 fused to alkaline phosphatase are shown. Ret-
ina sections were untreated (A to D) or pretreated with heparinase III
(E) or chondroitinase ABC (F). cPTP1-AP conditioned medium was
used alone (A) or preincubated with heparin (B), HS (C), or chon-
droitin sulfate (D). The BL staining indicates cPTP1-AP binding.
Arrowheads indicate the retinal BL. pe, pigmented epithelium. Scale
bar, 0.1 mm.
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(lane c) or chondroitinase ABC (lane d). However, treatment
with heparinase III (lane b) reduced agrin’s size to 250 kDa,
corresponding to its core protein. Similarly, the molecular
mass of collagen XVIII was reduced from 300 kDa to the
180-kDa core protein (lane f). Chondroitinase ABC treatment
had no effect (lane h), whereas collagenase removed any trace
of collagen XVIII (lane g). When the same HfV samples were
probed with the cPTP1-VSV conditioned medium in the blot
overlay assay, two bands, corresponding in size to agrin and
collagen XVIII, were observed in the untreated (lane i) and
chondroitinase ABC-treated (lane l) samples. Heparinase III
digestion (lane j) completely removed any signal on the over-
lay, showing that cPTP binding requires the presence of HS
chains. This agrees with the RAP in situ results described
above. Finally, collagenase preincubation (lane k) specifically
removed the lower-molecular-weight band, corresponding to
collagen XVIII.
The same patterns were obtained when purified agrin (Fig.
4B) or purified collagen XVIII (Fig. 4C) samples were enzyme
treated and probed in immunoblots or overlay assays. The
collagen XVIII blots (Fig. 4C) are more smeared than the
fresh HfV samples, presumably due to partial degradation
during the purification steps. Altogether, these data suggest
that agrin and collagen XVIII can act as binding partners for
cPTP, irrespective of the cPTP fusion tag used (AP or
VSV), and that these interactions occur necessarily via their
HS chains.
Overlapping expression of cPTP, agrin, and collagen
XVIII in the developing chick retina. cPTP, agrin, and colla-
gen XVIII are expressed in the embryonic nervous system in a
developmentally regulated manner (36, 38, 52, 71). We exam-
ined whether the expression patterns of cPTP and the pro-
posed ligands are juxtaposed, as would be expected if they were
to interact in vivo. At E6 cPTP is localized in retinal axons in
the optic fiber layer (OFL) in close contact with the BL (Fig.
5A). Agrin (Fig. 5C) and collagen XVIII (Fig. 5E) are local-
ized at E6 mainly in the BL, which forms part of the complex
substrate on which the retinal ganglion cells (RGCs) extend
their axons. At E10, when the retinal plexiform layers have
formed, cPTP is localized mainly in the OFL and in the inner
plexiform layer (IPL) (Fig. 5B). Agrin, produced like cPTP by
FIG. 4. cPTP binds agrin and collagen XVIII via their HS chains.
An HSPG-enriched fraction from chicken embryo vitreous bodies (A),
purified agrin (B), and purified collagen XVIII (C) samples, separated
by SDS–6% polyacrylamide gel electrophoresis, were transferred to
nitrocellulose and probed with antibodies specific for agrin or collagen
XVIII or were incubated with cPTP1-VSV conditioned medium.
cPTP1-VSV was detected using antibody to VSV. Samples were
either not treated with enzymes (lanes a, e, and i) or predigested with
heparinase III (lanes b, f, and j), collagenase (lanes c, g, and k), or
chondroitinase ABC (lanes d, h, and l). Arrows in panel A indicate the
two bands corresponding in molecular mass to agrin (upper arrow) and
collagen XVIII (lower arrow) observed in the blot overlay assay.
FIG. 5. Expression patterns of cPTP, agrin, and collagen XVIII in
the developing chick retina. E6 (A, C, and E) and E10 (B, D, and F)
chick retina sections were probed with antibodies to cPTP (A and B),
agrin (C and D), and collagen XVIII (E and F). At E6, cPTP is
strongly expressed in the retinal axons (outer fiber layer [OFL]), while
both agrin and collagen XVIII show strong expression in the juxta-
posed BL. At E10, cPTP shows strong expression, mainly in neurite
layers: OFL and IPL (inner plexiform layer). Agrin expression overlaps
in fiber layers and is also a major constituent of the BL along with
collagen XVIII. RGC, retinal ganglion cell layer; INL, inner nuclear
layer; OPL, outer plexiform layer; PE, pigmented epithelium. White
arrowheads indicate the BL staining. Scale bar, 0.1 mm.
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the RGCs, is present in the OFL and IPL but also accumulates
in large amounts in the BL (Fig. 5D). Collagen XVIII, how-
ever, produced by the ciliary body (39), is present only on the
retinal inner surface, representing the BL (Fig. 5F).
The expression patterns described above suggest that cPTP
would indeed be able to interact with both agrin and collagen
XVIII during eye development.
The first Ig domain of cPTP contains a putative heparin-
binding site. Basic amino acid clusters located on the surface
of extracellular domains of proteins are likely to bind polyan-
ionic glycosaminoglycan chains (for a review, see reference 42).
Using the SWISS-MODEL (v3.5) automated protein model-
ling server (31), we obtained three-dimensional (3D) models
for all the Ig domains and three out of four FNIII domains of
cPTP1 (except the FNIII-4 domain, which had less than 30%
identity to any 3D structure in the Protein Data Bank [PDB]).
Several positively charged clusters were observed on the mo-
lecular surfaces (computed using the Swiss-PdbViewer v3.6b2
program [30]), the most prominent being in the Ig-1 domain
(Fig. 6A). This cluster consists mainly of a -hairpin formed by
strands C and C (Fig. 6B) and contains the sequence
R62VTWNKKGKKVNSQR76, plus the side chains of Arg96
and Arg99, from a loop between the E and F strands. The
Ig-1 domain homology model was generated using telokin as a
template (39.3% identity; PDB codes 1FHG and 1TLK), a
typical Ig superfamily I-set structure. Twenty-four out of the 35
key structural residues as defined in reference 4 are identical,
representing all the major secondary structures and most of the
peripheral regions (Fig. 6C).
The cluster described above in the cPTP Ig-1 domain con-
tains a BBxBB motif suggested to interact optimally with HS
chains (where B represents Arg or Lys) (42). Other proteins
containing heparin/HS binding sites located in I-set Ig domains
have been described, including the classical examples: neural
cell adhesion molecule (NCAM) and fibroblast growth factor
(FGF) receptors (FGFRs). High-resolution 3D structures of
both NCAM (1EPF, X-ray structure) (47) and FGFR1 (1CVS,
X-ray structure) (61) have recently been published, and these
were aligned with the cPTP Ig-1 model using Swiss-Pdb
Viewer (Fig. 6C). The proposed heparin-binding site of cPTP
is perfectly conserved in its mouse and human orthologues and
aligns well with the heparin-binding site found in NCAM (14).
However, the location of the FGFR1 heparin-binding site does
not seem to overlap, suggesting a different molecular architec-
ture of the FGFR1-heparin complex.
The heparin-binding site of cPTP is essential for binding
to the retinal BL. To test the accuracy of the molecular mod-
elling prediction, we mutated the charged amino acids in the
putative heparin-binding site of the Ig-1 domain and, as con-
trols, other basic clusters present in cPTP Ig domains 2 and 3.
Several basic clusters are also present in the membrane-prox-
imal FNIII-4 domain. However, a cPTP1 extracellular con-
struct lacking this FNIII-4 domain, termed FN3-AP, bound
in a similar way to full-length cPTP1 in RAP in situ assays
(see Fig. 8A and B). Therefore, FNIII-4 does not contain the
BL HSPG binding site. The FN3-AP construct was used as a
backbone for incorporation of further mutations, as shown in
Fig. 7A. Mutations M1, M2, M3, and M4 are all directed to the
charged amino acids from the putative heparin/HS binding site
in Ig-1. Mutation M5 targets a basic cluster in Ig-2, and M6
targets a similar cluster in the loop connecting Ig-2 and Ig-3.
All constructs were transfected into 293T cells, and the cells
produced essentially equal amounts of fusion protein in the
conditioned media (data not shown). All the mutations di-
rected at the large basic cluster in Ig-1 (Fig. 6A) showed im-
paired heparin binding in solid-phase assays (Fig. 7B). Binding
of M5 and M6 constructs was not significantly affected. The
severely reduced binding properties of the M1 to M4 mutants
precluded the measurement of Kd values.
The mutated constructs were tested on E6 chick retina sec-
tions by RAP in situ. The BL binding pattern observed corre-
lated with the solid-phase heparin binding profile (Fig. 8).
Therefore, we conclude that the heparin/HS binding site was
correctly predicted by molecular modelling. This site, which is
highly conserved in the orthologues of cPTP (Fig. 6C), is
essential for the binding of cPTP1 ectodomains to the BL
HSPGs.
Müller glia endfeet contain HSPG and non-HSPG binding
sites for cPTP. Radial Müller glial cells are the only nonneu-
ronal cell type in the chicken retina. RAP in situ experiments
demonstrate that in addition to the BL ligand(s), cPTP binds
strongly to radial glia endfeet in contact with the BL. This
interaction contributes to the role of cPTP in neurite growth
and in maintenance of growth cone lamellipodia (33, 51). Here
we have assessed whether or not the endfeet binding sites are
also HSPGs.
Unfixed preparations of retinal basal laminae, with glial end-
feet attached, were used for RAP in situ experiments. Both
heparin addition and heparinase III treatment diminished
cPTP1-AP binding on glial endfeet significantly (Fig. 9B and
C). Unlike results in fixed cryosections, however (Fig. 3B), this
interaction was not blocked completely. In addition, several
cPTP1 mutant constructs exhibited reduced binding to the
glial endfeet (Fig. 9H, I, and J), but again there was residual
cPTP binding. Neither chondroitin sulfate nor chondroitinase
ABC pretreatment could significantly impair the interaction
between cPTP and its ligands expressed on glial endfeet (Fig.
9D and E). These observations suggest that the glial endfeet, a
highly differentiated area of the Müller glia, express both an
HSPG and a non-HSPG class of cPTP ligands.
DISCUSSION
Cell adhesion molecule-like RPTPs are emerging as a major
class of molecules involved in regulating neural development,
including axon growth and guidance, synaptic function, and
nerve repair (41, 78, 84; also reviewed in references 6, 55, 72,
and 79). Currently, little is understood regarding the molecular
mechanisms of RPTP signaling, one reason being that in only
a few cases are their interaction partners known. Where ho-
mophilic binding has been demonstrated between RPTPs, for
example with RPTP (8), RPTP (62), or RPTP (82), it is not
understood how, or even if, such binding directly influences
RPTP signaling. Where heterotypic ligands have been pro-
posed, it is clearer that ligand binding can influence phospha-
tase activity, either positively (66) or negatively (53). To ad-
vance our understanding it will be necessary to define many
more ligand classes for the RPTPs.
cPTP has recently been implicated in promoting intrareti-
nal axon growth and controlling the growth cone morphology
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FIG. 6. Structural model of the Ig-1 domain of cPTP and sequence alignment with the Ig domains of telokin, NCAM, and FGFR1.
(A) Electrostatic surface representation of the Ig-1 domain of cPTP; blue and red represent positive and negative electrostatic potential,
respectively. The large positive-potential patch represents the putative heparin binding site. Basic residues are labeled in yellow and numbered
according to Stoker (69). (B) Ribbon view of the predicted folding with the same orientation as in panel A. N and C denote the amino and carboxyl
termini. The  strands are labeled, from A to G, according to the telokin fold. (C) Structure-based sequence alignment between telokin (the
template used for modelling) and the heparin-binding Ig domains of cPTP, NCAM, and FGFR1. The corresponding sequences of the mouse and
human orthologues of cPTP (mPTP and hPTP) are included. The heparin-binding sites are highlighted in blue (proposed site for cPTP). The
telokin key structural residues and their conserved equivalents in cPTP are highlighted in green. The  strands are underlined. The secondary
structure definitions were reported in the following sources: for telokin, reference 44; for NCAM-Ig2, reference 47; and for FGFR1-Ig2, reference
61. This figure was made using the Swiss-PdbViewer v3.6b2 (30).
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of RGCs (51). Putative, heterotypic ligands for cPTP have
been localized on Müller glia endfeet and RGC neurites and in
the retinal BL (33, 51). The retinal BL (inner limiting mem-
brane) is a 50- to 70-nm-thick extracellular matrix sheet sepa-
rating the retina from the vitreous body. Its major constituents
include laminins, nidogen, collagen IV, HSPGs (mainly agrin
and collagen XVIII), and a chondroitin sulfate proteoglycan
(39). The retinal BL is an excellent substrate for axon growth
in vitro. In vivo, during the intraretinal axon outgrowth (E3 to
E7 in chick), axons grow initially on the BL and a layer formed
by radial glia endfeet (34). Accordingly, enzymatic disruption
of the BL severely perturbs retinal architecture and axonal
outgrowth (37). Our solid-phase binding assays have not de-
tected interactions between cPTP and laminin 1, laminin 2,
fibronectin, or collagen IV (McKinnell and Stoker, unpub-
lished data). However, cPTP binds heparin with high affinity
as well as the HS chains of HSPGs agrin and collagen XVIII.
In addition, using molecular modelling, we have identified a
heparin/HS binding site in the first Ig domain of cPTP, which
is necessary for these interactions. In our previous work we
showed that both the Ig and FNIII domains of cPTP are
required for ligand binding, at least under RAP in situ condi-
tions (33). Therefore, it appears that the HS binding site in the
first Ig domain described here is essential but not sufficient for
the interaction with HSPGs. The FNIII domains may be re-
quired either to achieve an appropriate functional conforma-
tion or to interact with other ligands in a putative cPTP
signaling complex.
HSPGs are well established as modulators of neurite out-
growth. Previous studies have reported that HSPGs enhance
the growth-promoting abilities of laminin and NCAM (re-
viewed in reference 7) and of basic FGF (12). Heparinase III
treatment of cell-free basal laminae greatly inhibited the
growth rate and distribution density of RGC axons (12) and
induced aberrant growth of axons in cultured insect wing ap-
pendages (83). In Xenopus, heparitinase removal of HS chains
FIG. 7. Identification of the cPTP heparin-binding site by site-
directed mutagenesis. (A) Basic residues in the heparin-binding site in
domain Ig-1 (mutations M1, M2, M3, and M4), another cluster in Ig-2
(mutation M5), or in the loop connecting Ig-2 and Ig-3 (mutation M6)
were replaced with alanine. wt corresponds to the original cPTP
sequence. (B) The mutated proteins were tested in solid-phase binding
assays for binding to heparin-BSA. Bars represent means 	 standard
errors of three determinations.
FIG. 8. The heparin/HS binding site in domain Ig-1 is essential for
retinal BL binding. Receptor affinity probe assays were performed
using cPTP1-AP (A), FN3-AP (B), M1 (C), M2 (D), M3 (E), M4
(F), M5 (G), and M6 (H) conditioned media, respectively. The BL
staining indicates fusion protein binding. Arrowheads indicate the
retinal BL. pe, pigmented epithelium. Scale bar, 0.1 mm.
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during optic tract formation retards retinal axon elongation;
later HS removal, after axons have extended to the tract, elicits
a tectal bypass phenotype (81). Moreover, addition of exoge-
nous HS chains to the developing Xenopus optic pathway se-
verely disrupted target recognition (81). These effects have
been attributed, at least in part, to the disruption of FGF
signaling. Our present data suggest that further signaling re-
ceptors that bind to HSPGs, including cPTP, may also be
directly affected in these assays.
The HSPGs agrin and collagen XVIII are the first hetero-
typic binding partners described for cPTP. These interactions
can not only bring further insight to our understanding of the
molecular mechanisms behind currently known cPTP func-
tions but also suggest novel ones. Agrin, for example, is abun-
dant in axonal pathways of the chick central nervous system,
such as the optic nerve and the tecto-bulbar pathway (36). The
temporal coincidence of its expression with axonal outgrowth
suggests a growth-promoting role for agrin, as has also been
proposed for cPTP (51). Surprisingly, though, purified agrin
displays an inhibitory activity for neurite outgrowth in vitro
(36). However, a large variety of molecules bind in vivo to
agrin via its HS chains, protein core, or both, including lami-
nin-1, thrombospondin, fibronectin, FGF2, merosin (laminin-
2), and pleiotrophin (15). All of these are in turn potent sub-
strates for neurite extension, and their binding to HSPGs is
important for modulating this activity. A functional interaction
between agrin and cPTP may or may not involve such mole-
cules as well. Furthermore, agrin is expressed in several iso-
forms. Alternative promoter and first (N-terminal) exon usage
defines a long (LN) and short (SN) isoform (11, 56). LN is
secreted and incorporated into the BL, while SN remains at-
tached on the neuronal surface. The purified agrin used as a
substrate for axon growth experiments in vitro was LN,
whereas the antibody we have used in this study does not
discriminate between the two isoforms (36). It is possible,
therefore, that the agrin involved in neurite outgrowth modu-
lation is of the SN type. Both isoforms mentioned above have
the potential to interact with cPTP either as a ligand (LN
agrin) or as a coreceptor on the neuronal surface (SN agrin).
Which one of these interactions has functional consequences is
still to be determined.
The best-characterized function for agrin remains its ability
to induce acetylcholine receptor clustering at neuromuscular
junctions (43). Transgenic animals have provided convincing
evidence for the essential role of LN agrin in triggering syn-
aptic differentiation (11; reviewed in reference 32). cPTP1 is
expressed on motor neurons and also binds to sites on muscles
in RAP in situ experiments (J. Chilton, F. Haj, and A. Stoker,
unpublished data). This interaction appears to be HS indepen-
dent, however, and its relationship, if any, to agrin has yet to be
determined.
Despite the large amount of data supporting the role of
agrin at neuromuscular junctions, less is known about its roles
in the brain, where it is a major HSPG. Recent reports (16, 22)
have revealed a potential role in Alzheimer’s disease. The
-amyloid peptide (A) accumulates as aggregates within se-
nile plaques and cerebrovascular deposits. A binds to the HS
chains of agrin in vitro, leading to the acceleration of A fibril
formation (16). Agrin also localizes to A deposits in brains
affected by Alzheimer’s disease. Interestingly, senile plaques
promote neurite outgrowth and usually contain numerous dys-
trophic neurites, events that may be dependent on FGF2,
which can associate with agrin’s HS chains (18). It would be
interesting to see whether PTP plays any role in this process.
In the avian retina, agrin is found mainly in the BL and retinal
plexiform layers (from E8 onwards) (35, 48), consistent with a
possible role in interneuronal synapse formation (49). Since
cPTP is present at high levels in the IPL (71) and, as reported
here, binds to agrin, this raises the possibility that cPTPmight
be involved in retinal synaptogenesis. There is evidence al-
ready that the highly related RPTP may be involved in mod-
ulating synaptic plasticity (77).
Another BL ligand for cPTP is collagen XVIII. Collagen
XVIII has recently emerged as a modulator of cell migration
and axon guidance (1), and a mutation in the human COL18A1
gene causes Knobloch syndrome, a disease involving vitreoreti-
nal degeneration (65). A 38-kDa C-terminal fragment termed
NC1 appears to be responsible for stimulating cell and axon
migration (1). Although this fragment has heparin-binding
FIG. 9. Müller glia endfeet express two classes of cPTP ligands.
Retinal basal laminae with glial endfeet attached were flat mounted
and probed by RAP in situ with conditioned media containing
cPTP1-AP (A to E), FN3-AP (F), M1 (G), M2 (H), M3 (I), M4 (J),
M5 (K), and M6 (L). Heparin addition (B) or heparinase III pretreat-
ment (C) reduces binding compared to control treatments (A and F)
but does not abolish it. cPTP mutants with impaired heparin-binding
properties also show reduced binding on glial endfeet (H to J). Chon-
droitin sulfate addition (D) or chondroitinase ABC pretreatment
(E) does not affect cPTP binding significantly. Arrows indicate ring-
like endfeet. Scale bar, 10 m.
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ability, its neuronal receptor has not been identified. We found
that binding of cPTP to collagen XVIII is dependent on the
integrity of the latter’s HS chains, at least in blot-overlay as-
says, although we cannot rule out direct protein-protein inter-
actions. NC1 contains a putative O-glycosylation site, although
it is not clear yet whether it is glycosylated in vivo. It will be of
interest to see if RPTP also acts as a receptor for NC1/
endostatin, considering the involvement of both proteins in
neurite growth and guidance.
The HS chains of agrin and collagen XVIII may directly
regulate the phosphatase activity of cPTP as is seen with
ligands interacting with other RPTPs (53, 66). Whether or not
such regulation occurs through receptor dimerization, which
occurs with certain RPTPs (reviewed in reference 3), remains
to be seen. Given that HS chains are highly variable and com-
plex, it may be unlikely that there is a singular HS structure
that acts as a specific ligand for cPTP. Instead, one likely way
in which HSPGs could interact with cPTP is by acting as a
facilitator of either receptor oligomerization or the binding of
further, cognate ligands. An example of this is seen with the
cobinding of FGF and HS to the FGF receptor, producing a
supramolecular complex with full signaling potential (64). If
HSPG-cPTP interactions represent part of a multiprotein
signaling complex necessary for regulating the RPTP, then the
characterization of additional components of this complex will
be essential. It is also feasible that binding of HS to cPTP
represents an adhesive function rather than a signaling func-
tion, and this will require further investigation.
We provide evidence that glial endfeet contain at least two
binding partners for cPTP. Previous work of members of our
group demonstrated that Müller glia endfeet contain ligands
for cPTP and that interactions with these ligands sustain
neurite outgrowth (51). Here we have shown that endfeet
contain HS-dependent binding sites for cPTP. It is possible
that interactions between these sites and cPTP lead at least in
part to the axonal phenotype observed earlier (51). However,
we also report that endfeet contain non-HS binding sites for
cPTP, which remain to be characterized. These binding sites
were not evident on cultured Müller glia, where cPTP binding
was entirely sensitive to heparinase treatment and heparin
competition (Aricescu, unpublished data). The non-HS bind-
ing sites on endfeet are also apparently removed or masked by
methanol fixation, both in flat-mounted basal laminae and in
tissue sections. Glial endfeet, in both the retina and tectum, are
highly differentiated structures (9, 67). Tectal endfeet, for ex-
ample, specifically accumulate ephrin B1 (9), and axon out-
growth experiments in vitro demonstrate that Müller glia are
highly polarized (67). As previously suggested (51), the endfeet
contain a rich mixture of positive and negative cues for neurite
outgrowth, and it is therefore possible that cPTP is interact-
ing, perhaps simultaneously, with at least two ligand types on
endfeet, with the net effect of promoting neurite elongation.
In conclusion, we demonstrate that cPTP has a novel, hep-
arin binding activity and that its ability to bind to the retinal BL
is mediated by HS chains of extracellular matrix HSPGs. These
matrix HSPGs are identified as agrin and collagen XVIII and
are the first heterotypic ligands identified for cPTP. These
HSPGs may be ligands in their own right or may act as partners
in presenting other ligand proteins to cPTP. Further investi-
gations will clarify the direct effect of HSPGs on cPTP func-
tion, helping us to understand how extracellular ligands regu-
late RPTP function and how such interactions in turn influence
axon development.
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